Peptides for anti-aging and longevity
Aging isn't one process — it's cellular housekeeping slowing down on many fronts at once: shorter telomeres, tired mitochondria, slower skin turnover. Peptides for anti-aging (epithalon, GHK-Cu, NAD, and others) each target one of those fronts.
These articles explain the biology in plain terms and are careful about the difference between findings in a lab dish and proven results in people. Everything offered here is prescription-only, reviewed by a licensed provider. None of them stops the clock, and the honest question is always which front matters for you.
44 articles on this topic
-

MOTS-c Before and After: What Research Shows
MOTS-c before and after photos are not clinical evidence. Human research has measured exercise and metabolic markers, but no completed study has published visible results from giving native MOTS-c—the exact peptide, not an altered analogue—to people.
-

SS-31 Protocol: What the Trials Actually Used
There is no single SS-31 cycle supported by human research. The useful evidence is narrower: a labeled plan for one rare disease and several trial schedules that cannot be copied into personal dosing advice.
-

Sermorelin Before and After: A Research Timeline
The research shows hormone changes within weeks, not a predictable visible transformation. Here is what small adult studies measured at two, six, and 16 weeks.
-

SS-31 and MOTS-c: Can You Take Them Together?
They are both mitochondrial peptides, and that is about where the similarity stops. No published trial has given people both at once — here is what each one has behind it.
-

MOTS-c Cycle: Nobody Has Established One
The word “cycle” came from bodybuilding, not from any MOTS-c research. Every study that has actually given the peptide — the mouse work, and the one human trial now running — dosed it straight through, with no weeks off.
-

MOTS-c Half-Life: What Is Actually Known
No published study has measured how long the body takes to clear a dose of MOTS-c. Here is what the rodent work, the exercise data and one unpublished Phase 1 trial actually show.
-

What Is Sermorelin Used For? A Plain Answer
Geref received approvals in 1990 for testing pituitary growth hormone release and in 1997 for children with growth failure from growth hormone deficiency. Adults are prescribed it today for sleep, body composition and recovery — uses that rest on a handful of small studies.
-

CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-

Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
-

Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-

Sermorelin for Men: Testosterone, Muscle & Sleep
Sermorelin can stimulate growth-hormone release when the pituitary responds, but it is not testosterone therapy. Small studies in older men found biochemical changes and mixed body-composition or strength results, with no reliable sleep or recovery benefit established.
-

Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-

SS-31 Benefits: What Human Trials Actually Show
The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.
-

Is NAD a Peptide? What NAD+ Actually Is
NAD+ is a dinucleotide coenzyme, not a peptide. Its chemistry, cellular jobs, and evidence are different from the peptide therapies it often appears beside.
-

Sermorelin for Women: Evidence and Menopause
Sermorelin can raise growth-hormone output in women when the pituitary responds, but female-specific trials are small and mostly use related GHRH compounds. It is not menopause hormone therapy, and the evidence does not show reliable gains in sleep, libido or lean mass for women.
-

Epitalon Dosage: How a Prescriber Decides
Published evidence does not establish a standard dose. One small human AEDG study used 0.5 mg daily under the tongue for 20 days; injection-cycle numbers often come from animal work or studies of a different pineal extract.
-

Sermorelin Benefits: What the Trials Found
In the best controlled study of the modified analogue [Nle27]GHRH(1-29)-NH2 in older adults, nocturnal growth hormone rose, IGF-1 climbed within two weeks, skin thickened — and lean body mass increased in men only. The specificity is the point.
-

Ipamorelin Benefits, Side Effects, Legal Status
Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.
-

Epitalon Benefits, Sorted by Evidence Tier
The most-cited animal experiment gave 54 mice per group monthly doses for life and found mean lifespan unchanged, maximum lifespan up 12.3%, and leukemia down six-fold.
-

The Thymulin Peptide Needs Zinc to Work
Thymulin is inert until a zinc ion binds it at a 1:1 molar ratio — and most published results in its literature come from mice, rats, or cell culture.
Page 2 of 3 · 44 articles